Product overview

Name Lestaurtinib
Alternative names CEP-701; KT-5555
Purity >99%
Description Potent, non-selective tyrosine kinase inhibitor
Write Your Own Review
You're reviewing:Lestaurtinib
Rate this item:

Biological Data

Biological description Potent and non-selective tyrosine kinase inhibitor. Inhibits JAK2 and JAK3 (IC50 values are 0.9 and 3 nM respectively). Also inhibits TrkA, TrkB, TrkC and FLT3 and prevents phosphorylation of STAT5. Shows anti-proliferative and anti-tumor actions.

Solubility & Handling

Storage instructions -20°C (desiccate)
Solubility overview Soluble in DMSO (100mM) or ethanol (25mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >99%
Chemical name (9S,10S,12R)-2,3,9,10,11,12-Hexahyd ro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epo xy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1, 6]benzodiazocin-1-one
Molecular Weight 439.46
Chemical structure Lestaurtinib  [111358-88-4] Chemical Structure
Molecular Formula C26H21N3O4
CAS Number 111358-88-4
PubChem identifier 126565
SMILES O=C(NC3)C1=C3C(C4=CC=CC=C4N5[C@@]78C)=C5C2=C1C6=C(C=CC=C6)N2[C@](O7)(C[C@](CO)8O)[H]
InChiKey UIARLYUEJFELEN-LROUJFHJSA-N

References for Lestaurtinib

References are publications that support the biological activity of the product
  • Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.

    Iyer R et al (2010) Clin Cancer Res 16(5) : 1478-85.
  • Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

    Hexner EO et al (2008) Blood 111(12) : 5663-71.
  • Effect of FLT3 inhibition on normal hematopoietic progenitor cells.

    Weisel KC et al (2007) Ann N Y Acad Sci 1106 : 190-6.
  • The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.

    Miknyoczki SJ et al (1999) Ann N Y Acad Sci 880 : 252-62.

4 Item(s)